U.S. Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.85-1.11 (-2.65%)
At close: 4:03PM EDT

40.85 0.00 (0.00%)
After hours: 5:49PM EDT

People also watch
Full screen
Previous Close41.96
Bid40.85 x 400
Ask40.89 x 200
Day's Range40.79 - 41.48
52 Week Range37.20 - 45.58
Avg. Volume2,764,714
Market Cap96.2B
PE Ratio (TTM)46.00
Earnings DateN/A
Dividend & Yield1.95 (4.62%)
Ex-Dividend Date2017-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press2 hours ago

    Glaxo reports 2Q loss

    The Brentford Middlesex, Britain-based company said it had a loss of 9 cents per share. Earnings, adjusted for non-recurring costs and restructuring costs, were 70 cents per share. The results exceeded ...

  • Reuters3 hours ago

    GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs

    GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals ...

  • Reuters6 hours ago

    GSK gives up on rare diseases as gene therapy gets two customers

    GlaxoSmithKline is swimming against the tide by getting out of treatments for rare diseases at a time when rivals like Sanofi and Shire see the field as a rich seam for profits. Successful medicines for rare conditions are potentially very lucrative, since prices frequently run into hundreds of thousands of dollars, but patient numbers can be extremely low. New GSK Chief Executive Emma Walmsley announced the strategic review and potential divestment of rare diseases on Wednesday as part of a wide-ranging drive to streamline pharmaceutical operations.